Equities

AstraZeneca PLC

AZN:LSE

AstraZeneca PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)12,250.00
  • Today's Change80.00 / 0.66%
  • Shares traded160.92k
  • 1 Year change4.04%
  • Beta0.3716
Data delayed at least 20 minutes, as of May 02 2024 09:26 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year AstraZeneca PLC grew revenues 3.29% from 44.35bn to 45.81bn while net income improved 81.11% from 3.29bn to 5.96bn.
Gross margin82.17%
Net profit margin13.31%
Operating margin18.40%
Return on assets6.37%
Return on equity17.29%
Return on investment8.73%
More ▼

Cash flow in USDView more

In 2023, cash reserves at AstraZeneca PLC fell by 346.00m. However, the company earned 10.35bn from its operations for a Cash Flow Margin of 22.58%. In addition the company used 4.06bn on investing activities and also paid 6.57bn in financing cash flows.
Cash flow per share5.87
Price/Cash flow per share20.53
Book value per share19.29
Tangible book value per share-11.00
More ▼

Balance sheet in USDView more

AstraZeneca PLC has a Debt to Total Capital ratio of 47.95%, a lower figure than the previous year's 77.25%.
Current ratio0.8856
Quick ratio0.7009
Total debt/total equity0.9227
Total debt/total capital0.4795
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 80.88% while dividends per share growth only marginally increased 0.21%. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is above the industry average.
Div yield(5 year avg)2.48%
Div growth rate (5 year)1.10%
Payout ratio (TTM)0.00%
EPS growth(5 years)17.52
EPS (TTM) vs
TTM 1 year ago		34.45
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.